Literature DB >> 11790897

Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: potential for new biomarkers to aid in the diagnosis of breast cancer.

C P Paweletz1, B Trock, M Pennanen, T Tsangaris, C Magnant, L A Liotta, E F Petricoin.   

Abstract

Nipple aspirate fluid (NAF) has been used for many years as a potential non-invasive method to identify markers for breast cancer risk or early detection. Because individual markers have not been optimal, we are exploring the use of surface enhanced laser desorption and ionization time of flight (SELDI-TOF) mass spectrometry to identify patterns of proteins that might define a proteomic signature for breast cancer. SELDI-TOF was used to analyze a study set of NAF samples that included 12 women with breast cancer and 15 healthy controls (the latter included three women with an abnormal mammogram but subsequent normal biopsy). In this preliminary report, we present data showing that SELDI analysis of NAF is rapid, reproducible, and capable of identifying protein signatures that appear to differentiate NAF samples from breast cancer patients and healthy controls, including those with an abnormal mammogram who were later proven to be biopsy normal.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11790897      PMCID: PMC3851093          DOI: 10.1155/2001/674959

Source DB:  PubMed          Journal:  Dis Markers        ISSN: 0278-0240            Impact factor:   3.434


  43 in total

Review 1.  Clinical applications of proteomics: proteomic pattern diagnostics.

Authors:  Emanuel E Petricoin; Cloud P Paweletz; Lance A Liotta
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-10       Impact factor: 2.673

Review 2.  Proteomic dissection of dome formation in a mammary cell line.

Authors:  I Zucchi; R Dulbecco
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-10       Impact factor: 2.673

3.  Diagnostic molecular pathology, part 2: proteomics and clinical applications of molecular diagnostics in hematopathology.

Authors:  Georges J Netto; Rana Saad
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

Review 4.  Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Authors:  Manfred Dietel; Christine Sers
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

Review 5.  Reverse phase protein microarrays advance to use in clinical trials.

Authors:  Claudius Mueller; Lance A Liotta; Virginia Espina
Journal:  Mol Oncol       Date:  2010-10-16       Impact factor: 6.603

Review 6.  Neuroproteomics as a promising tool in Parkinson's disease research.

Authors:  Ilse S Pienaar; William M U Daniels; Jürgen Götz
Journal:  J Neural Transm (Vienna)       Date:  2008-06-04       Impact factor: 3.575

7.  Identification of a beta-casein-like peptide in breast nipple aspirate fluid that is associated with breast cancer.

Authors:  Edward R Sauter; Wade Davis; Wenyi Qin; Sarah Scanlon; Brian Mooney; Karen Bromert; William R Folk
Journal:  Biomark Med       Date:  2009-10       Impact factor: 2.851

8.  Differentiating proteomic biomarkers in breast cancer by laser capture microdissection and MALDI MS.

Authors:  Melinda E Sanders; Eduardo C Dias; Baogang J Xu; James A Mobley; Dean Billheimer; Heinrich Roder; Julia Grigorieva; Mitchell Dowsett; Carlos L Arteaga; Richard M Caprioli
Journal:  J Proteome Res       Date:  2008-04-04       Impact factor: 4.466

Review 9.  Proteomics in cancer screening and management in gynecologic cancer.

Authors:  Wei Hu; Weiguo Wu; Ryuji Kobayashi; John J Kavanagh
Journal:  Curr Oncol Rep       Date:  2004-11       Impact factor: 5.075

10.  Use of ProteinChip array surface enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) to identify thymosin beta-4, a differentially secreted protein from lymphoblastoid cell lines.

Authors:  Deborah L Diamond; Yanni Zhang; Alexander Gaiger; Molly Smithgall; Thomas S Vedvick; Darrick Carter
Journal:  J Am Soc Mass Spectrom       Date:  2003-07       Impact factor: 3.109

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.